Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor how well treatments are working for patients with a type of brain tumor called glioma, specifically those with a genetic change known as IDH mutation. Researchers want to see if a special imaging technique called amino acid PET can help predict how effective IDH inhibitor treatments are for these patients. The study is not yet recruiting participants, but it aims to include adults aged 65 to 74 who have had this imaging done to assess their response to treatment between February 2022 and November 2024.

If you or a family member have IDH-mutated gliomas and have received IDH inhibitor treatment, you may be eligible for this trial. Participants will undergo amino acid PET imaging, which is a non-invasive way to see how the treatment is working in the body. It's important to note that individuals who do not agree to the use of their medical data will not be included in the study. This trial could provide valuable insights into the effectiveness of current treatments for gliomas and help improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024
• Exclusion Criteria:
• • Individuals who have objected to the use of their data